 Like all non-commercial areas, these diseases are the responsibility of governments and philanthropy (including industry philanthropy).Currently, the pharmaceutical industry views research and development as highly risky.For this reason, resources are not often put into the field of NTDs (as diseases of the poor) and new chemical products are often expensive.